Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
The initiative by DKMS Foundation India is for below 12 years children suffering from transfusion-dependent thalassemia
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The kidney care provider has established over 40 dialysis centres, delivering more than 40,000 dialysis sessions
Report highlights growing confidence in digitalisation and AI, even as healthcare leaders remain concerned about workforce gaps, cybersecurity, and data readiness
Leadership transition strengthens Redcliffe Labs’ focus on scaling technology-led diagnostics, operational excellence, and preventive healthcare access
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Week-long Fire Safety Week 2026 campaign focuses on strengthening fire prevention, preparedness, audits, and emergency response across hospitals and healthcare facilities
Subscribe To Our Newsletter & Stay Updated